About Albrem
Albrem Biopharma innovation provides unique capabilities to improve product characteristics, consistency and quality, for recombinant proteins used in drug development, immunochemistry, and bioanalytical sciences. Our proprietary approaches leverage state of the art technologies, including cell-free protein synthesis and high throughput screening, to address a wide range of protein product needs.
Our team brings together deep and diverse knowledge in product development, and we leverage our extensive experience in GXP scale-up production of recombinant proteins to optimize the candidate selection and development process.
This strategy improves efficiency and accelerates advancement. Our cell-free expression approach is also valuable for difficult-to-express proteins that do not express well in cells due to toxicity or aggregation. The consistency and control available with cell-free protein production also removes the potential problems of genetic drift that can be observed in other production systems.
Custom Proteins. Faster Timelines. Smarter Biology.
Over the past two decades, it has become increasingly clear that access to well-characterized proteins and reagents is essential for the successful advancement of biotechnology products. Recent breakthroughs—such as AlphaFold and AI-driven modeling—have further highlighted the importance of rapid protein screening and profiling in the development, immunogenicity assessment, and stability testing of new drug candidates and immunochemistry reagents. It is also important to acknowledge that native starting structures also provide significant benefit, including good stability profiles and lower potential for immunogenicity.
Protein discovery and development requires a deep understanding of structure-function relationships and protein drug presentation strategies. This is particularly critical in the early stages, where thoughtful candidate selection and optimization can accelerate development timelines and reduce attrition rates. Incorporating advances in rapid prototyping, especially as enabled through cell-free protein synthesis, we can now combine the best technologies to evaluate, and refine, protein candidates with greater speed and precision. Starting with the end in mind we can optimize the product to better fit the appropriate application.
At Albrem Biopharma, we specialize in analyzing and selecting highly active, modified proteins derived from naturally occurring sequences, leveraging targeted modifications produced via cell-free synthesis. Our proprietary high-throughput workflows enable rapid screening and selection of proteins with desired activity profiles. We are positioned to quickly deliver milligram-scale quantities for testing—providing a foundation for further characterization, optimization, and scale-up for production. We also offer process development and manufacturing support.
Our approach offers capability to rapidly select, optimize, and provide mg level of proteins, to support custom reagents and therapeutics development. We can also provide support for developing non-canonical amino acid incorporation and protein conjugation.
We welcome the opportunity to collaborate with you on the development of custom proteins tailored to your specific needs.
For more information about services and support opportunities with Albrem Biopharma please contact us.